GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Net Change in Cash

Pharmaron Beijing Co (SZSE:300759) Net Change in Cash : ¥2,571 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Pharmaron Beijing Co's Net Change in Cash for the three months ended in Mar. 2024 was ¥-1,228 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,571 Mil.

Pharmaron Beijing Co Net Change in Cash Historical Data

The historical data trend for Pharmaron Beijing Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Net Change in Cash Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,134.98 -2,088.29 415.78 -1,410.00 4,429.40

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 630.76 485.10 -452.74 3,766.27 -1,227.61

Pharmaron Beijing Co Net Change in Cash Calculation

Pharmaron Beijing Co's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2753.539+-2250.833+3915.262+11.434
=4,429

Pharmaron Beijing Co's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=745.631+-467.094+-1512.601+6.457
=-1,228

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,571 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaron Beijing Co (SZSE:300759) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (SZSE:300759) » Definitions » Net Change in Cash
Comparable Companies
SZSE:002821 SHSE:603392 SHSE:600161 SZSE:002252 SZSE:002007 SZSE:002653 SHSE:603233 SHSE:688520 SZSE:301301 SHSE:688278 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
03759:Hong Kong 17Q1:Germany
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Website
https://www.pharmaron.com
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Lou Xiao Qiang Directors, executives
Zheng Bei Directors, executives

Pharmaron Beijing Co (SZSE:300759) Headlines

No Headlines